Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Research

HOXA9 promotes homotypic and heterotypic cell interactions that facilitate ovarian cancer dissemination via its induction of P-cadherin

Authors: Song Yi Ko, Honami Naora

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Abstract

Background

Epithelial ovarian cancer (EOC) is a lethal disease that frequently involves the peritoneal cavity. Dissemination of EOC is a multi-step process in which exfoliated tumor cells survive in the peritoneal fluid as multi-cellular aggregates and then form invasive implants on peritoneal surfaces. The mechanisms that control this process are poorly understood. We previously identified that high expression of the developmental patterning gene HOXA9 is associated with poor survival in EOC patients. In this study, we investigated the significance and mechanisms of HOXA9 in controlling aggregation and implantation of floating EOC cells.

Methods

HOXA9 was inhibited by shRNAs or expressed in EOC cells that were propagated in suspension cultures and in the peritoneal cavity of mice. Cell death was assayed by flow cytometry and ELISA. Cell aggregation, attachment and migration were evaluated by microscopy, transwell chamber assays and histopathologic analysis. DNA-binding of HOXA9 and its effect on expression of the cell adhesion molecule P-cadherin were assayed by chromatin immunoprecipitation, quantitative RT-PCR and Western blot. HOXA9 and P-cadherin expression was evaluated in publicly available datasets of EOC clinical specimens.

Results

We identified that HOXA9 promotes aggregation and inhibits anoikis in floating EOC cells in vitro and in xenograft models. HOXA9 also stimulated the ability of EOC cells to attach to peritoneal cells and to migrate. HOXA9 bound the promoter of the CDH3 gene that encodes P-cadherin, induced CDH3 expression in EOC cells, and was associated with increased CDH3 expression in clinical specimens of EOC. Inhibiting P-cadherin in EOC cells that expressed HOXA9 abrogated the stimulatory effects of HOXA9 on cell aggregation, implantation and migration. Conversely, these stimulatory effects of HOXA9 were restored when P-cadherin was reconstituted in EOC cells in which HOXA9 was inhibited.

Conclusion

These findings indicate that HOXA9 contributes to poor outcomes in EOC in part by promoting intraperitoneal dissemination via its induction of P-cadherin.
Appendix
Available only for authorised users
Literature
1.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 2013, 63: 11-30. 10.3322/caac.21166CrossRefPubMed
2.
Naora H, Montell DJ: Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer. 2005, 5: 355-366. 10.1038/nrc1611CrossRefPubMed
3.
4.
Sodek KL, Murphy KJ, Brown TJ, Ringuette MJ: Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev. 2012, 31: 397-414. 10.1007/s10555-012-9351-2PubMedCentralCrossRefPubMed
5.
Burleson KM, Casey RC, Skubitz KM, Pambuccian SE, Oegema TR, Skubitz AP: Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol. 2004, 93: 170-181. 10.1016/j.ygyno.2003.12.034CrossRefPubMed
6.
Abate-Shen C: Deregulated homeobox gene expression in cancer: cause or consequence?. Nat Rev Cancer. 2002, 2: 777-785. 10.1038/nrc907CrossRefPubMed
7.
Samuel S, Naora H: Homeobox gene expression in cancer: insights from developmental regulation and deregulation. Eur J Cancer. 2005, 41: 2428-2437. 10.1016/j.ejca.2005.08.014CrossRefPubMed
8.
Pearson JC, Lemons D, McGinnis W: Modulating Hox gene functions during animal body patterning. Nat Rev Genet. 2005, 6: 893-904. 10.1038/nrg1726CrossRefPubMed
9.
Taylor HS, Vanden Heuvel GB, Igarashi P: A conserved Hox axis in the mouse and human female reproductive system: late establishment and persistent adult expression of the Hoxa cluster genes. Biol Reprod. 1997, 57: 1338-1345. 10.1095/biolreprod57.6.1338CrossRefPubMed
10.
Ko SY, Barengo N, Ladanyi A, Lee JS, Marini F, Lengyel E, Naora H: HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Invest. 2012, 122: 3603-3617. 10.1172/JCI62229PubMedCentralCrossRefPubMed
11.
Patel IS, Madan P, Getsios S, Bertrand MA, MacCalman CD: Cadherin switching in ovarian cancer progression. Int J Cancer. 2003, 106: 172-177. 10.1002/ijc.11086CrossRefPubMed
12.
Quattrocchi L, Green AR, Martin S, Durrant L, Deen S: The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression. Virchows Arch. 2011, 459: 21-29. 10.1007/s00428-011-1082-1CrossRefPubMed
13.
Cheung LW, Leung PC, Wong AS: Cadherin switching and activation of p120 catenin signaling are mediators of gonadotropin-releasing hormone to promote tumor cell migration and invasion in ovarian cancer. Oncogene. 2010, 29: 2427-2440. 10.1038/onc.2009.523CrossRefPubMed
14.
Usui A, Ko SY, Barengo N, Naora H: P-cadherin promotes ovarian cancer dissemination through tumor cell aggregation and tumor-peritoneum tnteractions. Mol Cancer Res. 2014, 12: 504-513. 10.1158/1541-7786.MCR-13-0489PubMedCentralCrossRefPubMed
15.
Yu D, Wolf JK, Scanlon M, Price JE, Hung MC: Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 1993, 53: 891-898.PubMed
16.
Pasca di Magliano M, Hebrok M: Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer. 2003, 3: 903-911. 10.1038/nrc1229CrossRefPubMed
17.
Klaus A, Birchmeier W: Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008, 8: 387-398. 10.1038/nrc2389CrossRefPubMed
18.
Ranganathan P, Weaver KL, Capobianco AJ: Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer. 2011, 11: 338-351. 10.1038/nrc3035CrossRefPubMed
19.
Care A, Silvani A, Meccia E, Mattia G, Stoppacciaro A, Parmiani G, Peschle C, Colombo MP: HOXB7 constitutively activates basic fibroblast growth factor in melanomas. Mol Cell Biol. 1996, 16: 4842-4851.PubMedCentralCrossRefPubMed
20.
Coletta RD, Christensen K, Reichenberger KJ, Lamb J, Micomonaco D, Huang L, Wolf DM, Muller-Tidow C, Golub TR, Kawakami K, Ford HL: The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci U S A. 2004, 101: 6478-6483. 10.1073/pnas.0401139101PubMedCentralCrossRefPubMed
21.
Trinh BQ, Barengo N, Naora H: Homeodomain protein DLX4 counteracts key transcriptional control mechanisms of the TGF-beta cytostatic program and blocks the antiproliferative effect of TGF-beta. Oncogene. 2011, 30: 2718-2729. 10.1038/onc.2011.4PubMedCentralCrossRefPubMed
22.
Micalizzi DS, Wang CA, Farabaugh SM, Schiemann WP, Ford HL: Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth. Cancer Res. 2010, 70: 10371-10380. 10.1158/0008-5472.CAN-10-1354PubMedCentralCrossRefPubMed
23.
Yu Y, Davicioni E, Triche TJ, Merlino G: The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. Cancer Res. 2006, 66: 1982-1989. 10.1158/0008-5472.CAN-05-2360CrossRefPubMed
24.
Daftary GS, Troy PJ, Bagot CN, Young SL, Taylor HS: Direct regulation of beta3-integrin subunit gene expression by HOXA10 in endometrial cells. Mol Endocrinol. 2002, 16: 571-579.PubMed
25.
Zhu R, Wong KF, Lee NP, Lee KF, Luk JM: HNF1alpha and CDX2 transcriptional factors bind to cadherin-17 (CDH17) gene promoter and modulate its expression in hepatocellular carcinoma. J Cell Biochem. 2010, 111: 618-626. 10.1002/jcb.22742CrossRefPubMed
26.
Gumbiner BM: Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol. 2005, 6: 622-634. 10.1038/nrm1699CrossRefPubMed
27.
Halbleib JM, Nelson WJ: Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev. 2006, 20: 3199-3214. 10.1101/gad.1486806CrossRefPubMed
28.
Sivertsen S, Berner A, Michael CW, Bedrossian C, Davidson B: Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions. Acta Cytol. 2006, 50: 603-607. 10.1159/000326027CrossRefPubMed
29.
Veatch AL, Carson LF, Ramakrishnan S: Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Cancer. 1994, 58: 393-399. 10.1002/ijc.2910580315CrossRefPubMed
30.
Davidson B, Berner A, Nesland JM, Risberg B, Berner HS, Trope CG, Kristensen GB, Bryne M, Florenes AV: E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. J Pathol. 2000, 192: 460-469. 10.1002/1096-9896(2000)9999:9999<::AID-PATH726>3.0.CO;2-MCrossRefPubMed
31.
Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Ng T, Reynolds CP, Triche TJ, Sorensen PH: E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res. 2007, 67: 3094-3105. 10.1158/0008-5472.CAN-06-3259PubMedCentralCrossRefPubMed
32.
Kumar S, Park SH, Cieply B, Schupp J, Killiam E, Zhang F, Rimm DL, Frisch SM: A pathway for the control of anoikis sensitivity by E-cadherin and epithelial-to-mesenchymal transition. Mol Cell Biol. 2011, 31: 4036-4051. 10.1128/MCB.01342-10PubMedCentralCrossRefPubMed
33.
Taniuchi K, Nakagawa H, Hosokawa M, Nakamura T, Eguchi H, Ohigashi H, Ishikawa O, Katagiri T, Nakamura Y: Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. Cancer Res. 2005, 65: 3092-3099.PubMed
34.
Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 2009, 139: 871-890. 10.1016/j.cell.2009.11.007CrossRefPubMed
35.
Shi X, Bai S, Li L, Cao X: Hoxa-9 represses transforming growth factor-beta-induced osteopontin gene transcription. J Biol Chem. 2001, 276: 850-855. 10.1074/jbc.M005955200CrossRefPubMed
36.
Lessan K, Aguiar DJ, Oegema T, Siebenson L, Skubitz AP: CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am J Pathol. 1999, 154: 1525-1537. 10.1016/S0002-9440(10)65406-5PubMedCentralCrossRefPubMed
37.
Heyman L, Kellouche S, Fernandes J, Dutoit S, Poulain L, Carreiras F: Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro. Tumour Biol. 2008, 29: 231-244. 10.1159/000152941CrossRefPubMed
38.
Ko SY, Lengyel E, Naora H: The Mullerian HOXA10 gene promotes growth of ovarian surface epithelial cells by stimulating epithelial-stromal interactions. Mol Cell Endocrinol. 2010, 317: 112-119. 10.1016/j.mce.2009.12.025PubMedCentralCrossRefPubMed
39.
Chen GT, Tai CT, Yeh LS, Yang TC, Tsai HD: Identification of the cadherin subtypes present in the human peritoneum and endometriotic lesions: potential role for P-cadherin in the development of endometriosis. Mol Reprod Dev. 2002, 62: 289-294. 10.1002/mrd.10121CrossRefPubMed
40.
Van Marck V, Stove C, Van Den Bossche K, Stove V, Paredes J, Vander Haeghen Y, Bracke M: P-cadherin promotes cell-cell adhesion and counteracts invasion in human melanoma. Cancer Res. 2005, 65: 8774-8783. 10.1158/0008-5472.CAN-04-4414CrossRefPubMed
41.
Bauer K, Dowejko A, Bosserhoff AK, Reichert TE, Bauer RJ: P-cadherin induces an epithelial-like phenotype in oral squamous cell carcinoma by GSK-3beta-mediated Snail phosphorylation. Carcinogenesis. 2009, 30: 1781-1788. 10.1093/carcin/bgp175CrossRefPubMed
42.
Mandeville JA, Silva Neto B, Vanni AJ, Smith GL, Rieger-Christ KM, Zeheb R, Loda M, Libertino JA, Summerhayes IC: P-cadherin as a prognostic indicator and a modulator of migratory behaviour in bladder carcinoma cells. BJU Int. 2008, 102: 1707-1714. 10.1111/j.1464-410X.2008.08115.xCrossRefPubMed
43.
Rowlands TM, Symonds JM, Farookhi R, Blaschuk OW: Cadherins: crucial regulators of structure and function in reproductive tissues. Rev Reprod. 2000, 5: 53-61. 10.1530/ror.0.0050053CrossRefPubMed
44.
Lawrence HJ, Helgason CD, Sauvageau G, Fong S, Izon DJ, Humphries RK, Largman C: Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis. Blood. 1997, 89: 1922-1930.PubMed
45.
Radice GL, Ferreira-Cornwell MC, Robinson SD, Rayburn H, Chodosh LA, Takeichi M, Hynes RO: Precocious mammary gland development in P-cadherin-deficient mice. J Cell Biol. 1997, 139: 1025-1032. 10.1083/jcb.139.4.1025PubMedCentralCrossRefPubMed
46.
Wu Q, Lothe RA, Ahlquist T, Silins I, Trope CG, Micci F, Nesland JM, Suo Z, Lind GE: DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer. 2007, 6: 45- 10.1186/1476-4598-6-45PubMedCentralCrossRefPubMed
47.
Soshnikova N, Duboule D: Epigenetic regulation of vertebrate Hox genes: a dynamic equilibrium. Epigenetics. 2009, 4: 537-540. 10.4161/epi.4.8.10132CrossRefPubMed
48.
Cha TL, Zhou BP, Xia W, Wu Y, Yang CC, Chen CT, Ping B, Otte AP, Hung MC: Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science. 2005, 310: 306-310. 10.1126/science.1118947CrossRefPubMed
49.
Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, Coppola D, Nicosia SV, Cheng JQ: Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene. 2000, 19: 2324-2330. 10.1038/sj.onc.1203598CrossRefPubMed
50.
Zhang CC, Yan Z, Zhang Q, Kuszpit K, Zasadny K, Qiu M, Painter CL, Wong A, Kraynov E, Arango ME, Mehta PP, Popoff I, Casperson GF, Los G, Bender S, Anderes K, Christensen JG, VanArsdale T: PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity. Clin Cancer Res. 2010, 16: 5177-5188. 10.1158/1078-0432.CCR-10-1343CrossRefPubMed
51.
Kenny HA, Krausz T, Yamada SD, Lengyel E: Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer. 2007, 121: 1463-1472. 10.1002/ijc.22874CrossRefPubMed
Metadata
Title
HOXA9 promotes homotypic and heterotypic cell interactions that facilitate ovarian cancer dissemination via its induction of P-cadherin
Authors
Song Yi Ko
Honami Naora
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-170

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue

Research

Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review

Research

Reciprocal regulation of MicroRNA-99a and insulin-like growth factor I receptor signaling in oral squamous cell carcinoma cells

Research

IL-1β-induced activation of p38 promotes metastasis in gastric adenocarcinoma via upregulation of AP-1/c-fos, MMP2 and MMP9

Research

Reduced migration of MLH1 deficient colon cancer cells depends on SPTAN1

Short communication

Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab

Research

Downregulation of miR-610 promotes proliferation and tumorigenicity and activates Wnt/β-catenin signaling in human hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits